These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 30270567)

  • 21. Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis.
    Huthmacher JA; Meier JJ; Nauck MA
    Diabetes Care; 2020 Sep; 43(9):2303-2312. PubMed ID: 32910778
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fixed versus flexible combination of GLP-1 receptor agonists with basal insulin in type 2 diabetes: A retrospective multicentre comparative effectiveness study.
    Morieri ML; Rigato M; Frison V; Simioni N; D'Ambrosio M; Tadiotto F; Paccagnella A; Lapolla A; Avogaro A; Fadini GP
    Diabetes Obes Metab; 2019 Nov; 21(11):2542-2552. PubMed ID: 31364233
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Addition of or switch to insulin therapy in people treated with glucagon-like peptide-1 receptor agonists: A real-world study in 66 583 patients.
    Montvida O; Klein K; Kumar S; Khunti K; Paul SK
    Diabetes Obes Metab; 2017 Jan; 19(1):108-117. PubMed ID: 27629433
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glucagon-like peptide-1 receptor agonist and new-onset diabetes in overweight/obese individuals with prediabetes: A systematic review and meta-analysis of randomized trials.
    Yanto TA; Vatvani AD; Hariyanto TI; Suastika K
    Diabetes Metab Syndr; 2024 Jun; 18(6):103069. PubMed ID: 38963997
    [TBL] [Abstract][Full Text] [Related]  

  • 25. GLP1-RA Add-on Therapy in Patients with Type 2 Diabetes Currently on a Bolus Containing Insulin Regimen.
    Davies ML; Pham DQ; Drab SR
    Pharmacotherapy; 2016 Aug; 36(8):893-905. PubMed ID: 27340935
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients.
    Abd El Aziz MS; Kahle M; Meier JJ; Nauck MA
    Diabetes Obes Metab; 2017 Feb; 19(2):216-227. PubMed ID: 27717195
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Deintensification of basal-bolus insulin after initiation of GLP-1RA in patients with type 2 diabetes under routine care.
    Bonora BM; Rigato M; Frison V; D'Ambrosio M; Tadiotto F; Lapolla A; Simioni N; Paccagnella A; Avogaro A; Fadini GP
    Diabetes Res Clin Pract; 2021 Mar; 173():108686. PubMed ID: 33548335
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysis.
    Mantsiou C; Karagiannis T; Kakotrichi P; Malandris K; Avgerinos I; Liakos A; Tsapas A; Bekiari E
    Diabetes Obes Metab; 2020 Oct; 22(10):1857-1868. PubMed ID: 32476254
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of GLP-1 receptor agonists for type 2 diabetes treatment intensification after basal insulin failure.
    Joubert M; Reznik Y
    Diabetes Metab; 2017 Apr; 43 Suppl 1():2S34-2S38. PubMed ID: 28431670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The placebo response of injectable GLP-1 receptor agonists vs. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysis.
    de Wit HM; Te Groen M; Rovers MM; Tack CJ
    Br J Clin Pharmacol; 2016 Jul; 82(1):301-14. PubMed ID: 26935973
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparation of fixed-ratio (IDegLira and iGlarLixi) versus free combination of basal insulin and glucagon-like peptide-1 receptor agonist for uncontrolled type 2 diabetes: A systematic review and network meta-analysis.
    Weng J; Tao Y; Xu Z; Zhou S; Xiao D; Zhu Z; Zheng R; Yang Y; Chen Y
    J Evid Based Med; 2024 Jun; 17(2):370-376. PubMed ID: 38858300
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of a dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta-analysis.
    Yang Y; He L; Liu P; Wang J; Yang N; Li Z; Ping F; Xu L; Li W; Zhang H; Li Y
    Diabetes Obes Metab; 2024 Feb; 26(2):548-556. PubMed ID: 37860884
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characteristics of patients with type 2 diabetes mellitus newly treated with GLP-1 receptor agonists (CHADIG Study): a cross-sectional multicentre study in Spain.
    Conget I; Mauricio D; Ortega R; Detournay B;
    BMJ Open; 2016 Jul; 6(7):e010197. PubMed ID: 27466235
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glucagon-like peptide-1 receptor agonists versus insulin in inadequately controlled patients with type 2 diabetes mellitus: a meta-analysis of clinical trials.
    Wang Y; Li L; Yang M; Liu H; Boden G; Yang G
    Diabetes Obes Metab; 2011 Nov; 13(11):972-81. PubMed ID: 21651690
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combining a GLP-1 receptor agonist and basal insulin: study evidence and practical considerations.
    Carris NW; Taylor JR; Gums JG
    Drugs; 2014 Dec; 74(18):2141-52. PubMed ID: 25414121
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-world use of glucagon-like peptide-1 receptor agonists in youth with type 2 diabetes is associated with short-term improvements in HbA1c.
    Samuels SL; Chajecki A; Hu P; Kayser M; Weyman K; Pan B; Brown EA; Van Name M; Wolf RM
    Diabetes Obes Metab; 2024 Apr; 26(4):1305-1313. PubMed ID: 38229444
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular outcomes after initiating GLP-1 receptor agonist or basal insulin for the routine treatment of type 2 diabetes: a region-wide retrospective study.
    Longato E; Di Camillo B; Sparacino G; Tramontan L; Avogaro A; Fadini GP
    Cardiovasc Diabetol; 2021 Nov; 20(1):222. PubMed ID: 34774054
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Addition of glucagon-like peptide-1 receptor agonist therapy to insulin in C-peptide-positive patients with type 1 diabetes.
    Kuhadiya ND; Prohaska B; Ghanim H; Dandona P
    Diabetes Obes Metab; 2019 Apr; 21(4):1054-1057. PubMed ID: 30536789
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of insulin-GLP-1 receptor agonists combination in type 2 diabetes mellitus: a systematic review.
    Cimmaruta D; Maiorino MI; Scavone C; Sportiello L; Rossi F; Giugliano D; Esposito K; Capuano A
    Expert Opin Drug Saf; 2016 Dec; 15(sup2):77-83. PubMed ID: 27875915
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis.
    Castellana M; Cignarelli A; Brescia F; Perrini S; Natalicchio A; Laviola L; Giorgino F
    Sci Rep; 2019 Dec; 9(1):19351. PubMed ID: 31852920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.